Search
Lasalocid
go.drugbank.com/drugs/DB11423ExperimentalVet approvedLasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of _Streptomyces lasaliensis_.
Categories: Compounds used in a research, industrial, or household settingIsopentane
go.drugbank.com/drugs/DB16203InvestigationalIsopentane is under investigation in clinical trial NCT00752089 (Experimental Dentifrice Remineralization/fluoride Uptake in an in Situ Model).
AVI-014
go.drugbank.com/drugs/DB17086InvestigationalAVI-014 is an egg white-derived transgenic, glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).[A274441]
AVP-21D9
go.drugbank.com/drugs/DB17798InvestigationalAVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.[A259522]
MRT5005
go.drugbank.com/drugs/DB18260InvestigationalMRT5005 is a human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI).
TCB-008
go.drugbank.com/drugs/DB18352InvestigationalTCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.
FLT190
go.drugbank.com/drugs/DB18420InvestigationalFLT190 is a recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A.
Prizloncabtagene autoleucel
go.drugbank.com/drugs/DB18623InvestigationalC-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor, an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CARCTX120
go.drugbank.com/drugs/DB18625InvestigationalCTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
Avoplacel
go.drugbank.com/drugs/DB18659InvestigationalAvoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.[L48370]